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Introduction 
An emerging therapeutic application in     
immunology is the development of vaccines against       
cancer by using neoepitopes. A neoepitope is a        
peptide found only in the cancer state (coming from         
different gene expression or containing a mutation),       
that is able to generate an immune response.        
However, neoantigen discovery is hampered by the       
huge complexity of the immune system and the        
lack of experimental determinations. 
The immune system is able to elicit an immune         
response against foreign antigens. Generation of      
the immune response depends on i) the degradation        
of proteins by the proteasome, and ii) the        
presentation of those peptides to the T-cells by the         
major histocompatibility center (MHC).    
Particularly in cancer, MHC class I role is to         
present self peptides to the CD8+ T-cells. There are         
described more than 10,000 MHC class I alleles​1​,        
and it is expected that each of them is able to           
present around 5,000 different peptides. In contrast,       
a small fraction of peptides for less than 150 MHC          
class I alleles have been experimentally addressed.       
Current machine learning state-of-the art MHC      
binding predictors​2​,​3 are limited to deal only with        
the well characterized MHC class I alleles,       
hampering their application in personalized     
medicine. In this context we present uMHCpred, a        
de novo binding predictor that could give insights        
in the building of an universal model able to deal          
with the underrepresented MHC class I alleles. 
 
Methodology 
uMHCpred follows a frequency based approach      
that integrates the tridimensional structure of the       
MHC class I. More in detail, uMHCpred factorizes        
each residue of the peptide, building a position        
independent contact map. Then, the obtained      
contact map is used to classify each MHC by its          
structural similarity for each of the actorized       
peptide positions, archiving in this way a model        
that is no longer allele dependent. 
 
 
 
 
 
 
In this way, uMHCpred is able to predict de novo          
MHC class I alleles using training data coming        
from those alleles that have a similar binding        
environment. In order to assess the performance of        
the de novo predictions, we compared them with a         
model containing all available data by computing       
the Receiver Operator Characteristic (ROC) and its       
Area Under the Curve (AUC). 
 
Results 
Our results showed that uMHCpred can predict de        
novo binding of MHC alleles, such as       
HLA-A*02:01 (​Figure 1​), reaching an accurate      
prediction (AUC of 0.88), with a minimal loss in         
comparison with the model that also uses data from         
the predicted allele (AUC of 0.91). 
 
Figure 1​. ROC curves of the de novo prediction of          
HLA-A*02:01 (red) and the prediction that also       
uses data from the same allele (blue). 
 
Conclusions 
uMHCpred can make accurate predictions for all       
the MHC variants including the ones that are        
underrepresented in the available data.     
Additionally, it is able to predict which peptides        
could be the best theoretical binders of each allele.         
Furthermore, this results could open a world of        
possibilities towards the neoepitope finding for      
personalized medicine. 
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